Earnings ·
Boston Scientific reports Q3 net sales of $5.14B, up 1.5%, with adjusted EPS of $0.73
BSXBoston Scientific Corp
Boston Scientific reported third-quarter net sales of $5.138 billion, a 1.5 percent increase on both an operational and organic basis compared to the prior year period. GAAP net income attributable to common stockholders was $582 million, or $0.40 per share, down from $755 million, or $0.51 per share, a year ago. Adjusted earnings per share came in at $0.73, compared to $0.75 in the prior-year quarter. The company also provided updated full-year 2026 guidance, estimating net sales growth of approximately 4.25 percent on a reported basis and adjusted EPS between $3.16 and $3.18. Boston Scientific operates as a global medical technology leader providing devices and therapies for cardiovascular, neuromodulation, endoscopy, urology, and other therapeutic areas.